All In Biotech

Drug Trial Radar · NCT04295538

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Sep 6, 2020

Primary completion

Jan 26, 2026

Study completion Jan 26, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute traumatic cervical SCI. Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration. This study is "double-blinded", which means that neither trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Participants 18-75 years of age with a SCI will be enrolled. Approximately 54 participants will be enrolled in the study in approximately 49 sites worldwide. Participants will receive intravenous (IV) doses of elezanumab or placebo within 24 hours of injury and every 4 weeks thereafter through Week 48 for a total of 13 doses. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Spinal Cord Injury (SCI)

Interventions

  • ElezanumabDrug

    Solution for infusion; Intravenous (IV)

  • PlaceboDrug

    Solution for infusion; Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Upper Extremity Motor Score (UEMS)Time frame: 52 Weeks
  2. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 91 Weeks

Locations

41 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California Davis Health /ID# 224892

    Sacramento, California

  • Shepherd Center, Inc /ID# 230370

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine /ID# 218009

    Chicago, Illinois

  • University of Louisville Hospital /ID# 215948

    Louisville, Kentucky

  • Duplicate_Tufts Medical Center /ID# 225410

    Boston, Massachusetts

  • Brigham & Women's Hospital /ID# 216342

    Boston, Massachusetts

  • Duplicate_Boston University School of Medicine /ID# 218371

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center /ID# 218149

    Boston, Massachusetts

  • Regents of the University of Michigan /ID# 215890

    Ann Arbor, Michigan

  • Washington University-School of Medicine /ID# 215325

    St Louis, Missouri

  • Hackensack Univ Med Ctr /ID# 215754

    Hackensack, New Jersey

  • Jersey Shore University Medical Center /ID# 218162

    Neptune City, New Jersey

  • Rutgers New Jersey School of Medicine /ID# 216212

    Newark, New Jersey

  • Duplicate_Duke Cancer Center /ID# 216888

    Durham, North Carolina

  • Oregon Medical Research Center /ID# 227371

    Portland, Oregon

  • University of Pennsylvania /ID# 218662

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital /ID# 215460

    Philadelphia, Pennsylvania

  • University of Virginia Health /ID# 218117

    Charlottesville, Virginia

  • Sentara Norfolk General Hospital /ID# 218302

    Norfolk, Virginia

  • Virginia Commonwealth University Medical Center Main Hospital /ID# 217481

    Richmond, Virginia

  • West Virginia University Hospitals /ID# 217344

    Morgantown, West Virginia

  • Wisconsin Medical Center /ID# 215610

    Milwaukee, Wisconsin

  • Royal Adelaide Hospital /ID# 216953

    Adelaide, South Australia, Australia

  • Foothills Medical Centre /ID# 214790

    Calgary, Alberta, Canada

  • QEII - Health Sciences Centre /ID# 215249

    Halifax, Nova Scotia, Canada

  • The Ottawa Hospital Civic Campus /ID# 215270

    Ottawa, Ontario, Canada

  • Toronto Western Hospital /ID# 215214

    Toronto, Ontario, Canada

  • CIUSSS du Nord-de-l'ile-de-Montréal_Hopital du Sacré-Coeur de Montréal /ID# 215210

    Montreal, Quebec, Canada

  • The Chaim Sheba Medical Center /ID# 240917

    Ramat Gan, Tel Aviv, Israel

  • NHO Nagoya Medical Center /ID# 239617

    Nagoya, Aichi-ken, Japan

  • Funabashi Municipal Medical Center /ID# 225599

    Funabashi-shi, Chiba, Japan

  • Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141

    Iizuka-shi, Fukuoka, Japan

  • National Hospital Organization Murayama Medical Center /ID# 223492

    Musashimurayama-shi, Tokyo, Japan

  • Ajou University Hospital /ID# 241119

    Suwon, Gyeonggido, South Korea

  • Duplicate_Inha University Hospital /ID# 238890

    Junggu, Incheon Gwang Yeogsi, South Korea

  • Hospital Universitario Vall de Hebron /ID# 217794

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre /ID# 225354

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio /ID# 225692

    Seville, Spain

  • Hospital Nacional de Paraplejicos /ID# 225508

    Toledo, Spain

  • Hospital Universitario y Politecnico La Fe /ID# 217797

    Valencia, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.